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Summary
We used gene expression profiling to establish a molecular diagnosis of mantle cell lymphoma (MCL), to elucidate its
pathogenesis, and to predict the length of survival of these patients. An MCL gene expression signature defined a large
subset of MCLs that expressed cyclin D1 and a novel subset that lacked cyclin D1 expression. A precise measurement of
tumor cell proliferation, provided by the expression of proliferation signature genes, identified patient subsets that differed
by more than 5 years in median survival. Differences in cyclin D1 mRNA abundance synergized with INK4a/ARF locus
deletions to dictate tumor proliferation rate and survival. We propose a quantitative model of the aberrant cell cycle
regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy.
S I G N I F I C A N C E
From a mechanistic standpoint, our results demonstrate that mathematical models can reveal the synergism between oncogenic
events in a human cancer. The proliferation gene expression signature functioned as a quantitative integrator of multiple oncogenic
aberrations. As such, the proliferation signature was better at predicting length of survival than were other models based on the
individual oncogenic events. From a clinical standpoint, our gene expression-based model of survival provides the most precise
prognostic index yet described for MCL. Our survival model suggests that therapeutic modulation of the cell cycle has the potential
to significantly prolong the life of these patients.
CANCER CELL : FEBRUARY 2003 · VOL. 3 · COPYRIGHT  2003 CELL PRESS 185
R E P O R T
Introduction cal review. Since the t(11;14) translocation and cyclin D1 overex-
pression have been consistently associated with MCL, we mea-
sured cyclin D1 mRNA levels in each potential MCL case byMantle cell lymphoma (MCL) was originally identified as a mor-
phologically distinct subtype of non-Hodgkin’s lymphoma, and quantitative RT-PCR. Of the 101 cases with MCL histology, 92
expressed cyclin D1 mRNA, and these were considered thesubsequently the t(11;14) translocation was defined as a charac-
teristic molecular feature of this lymphoma subtype (Campo et “core” group of bona fide MCLs. We used Lymphochip DNA
microarrays (Alizadeh et al., 1999) to profile gene expression inal., 1999; Raffeld and Jaffe, 1991; Swerdlow and Williams, 2002;
Weisenburger and Armitage, 1996). This translocation leads to all 101 lymphoma cases with MCL morphology. For comparison,
we profiled gene expression in 20 cases of SLL and used pre-overexpression of cyclin D1, a D-type cyclin that is not usually
expressed at high levels in normal B lymphocytes (Rosenberg viously published gene expression data from two subgroups of
diffuse large B cell lymphoma (DLBCL), germinal center B cell-et al., 1991). Current WHO guidelines for the diagnosis of MCL
rely on morphological assessment supplemented with analysis like (GCB) DLBCL (134 cases), and activated B cell-like (ABC)
DLBCL (83 cases) (Rosenwald et al., 2002). Several thousandof cyclin D1 translocation or overexpression (Jaffe et al., 1999).
Cyclin D1 translocation and expression has been helpful in dis- genes were differentially expressed between MCL and the other
lymphoma subtypes with high statistical significance (p tinguishing MCL from other chronic B cell malignancies, such
as small lymphocytic lymphoma/chronic lymphocytic leukemia 0.001), and those “MCL signature genes” that were most highly
and differentially expressed in MCL are shown in Figure 1A (a(SLL/CLL), follicular lymphoma, and marginal zone lymphoma.
Nevertheless, some lymphomas that lack cyclin D1 expression complete listing of these genes is available at http://llmpp.nih.
gov/MCL).are morphologically similar to MCL and may be variant forms
of this lymphoma type (Yatabe et al., 2000). To create a gene expression-based diagnostic test for MCL,
we developed a Bayesian statistical method that was able toMCL accounts for 6% of all non-Hodgkin’s lymphomas and
a higher fraction of deaths from lymphoma, given that it is an distinguish MCL from other lymphoma subtypes. In brief, we
began by identifying the most differentially expressed genesincurable malignancy (Campo et al., 1999; Swerdlow and Wil-
liams, 2002; TNHLCP, 1997). The length of survival of MCL between cyclin D1-positive MCL and each of the other lym-
phoma types. These differentially expressed genes were com-patients following diagnosis is quite variable. The median sur-
vival in MCL is approximately 3 years, but some patients have bined to form a series of binary predictors that estimated the
probability that a particular lymphoma sample was MCL or onean aggressive disease to which they succumb in less than 1
year. Other patients have a comparatively indolent disease, and of the other lymphoma types. We used a cutoff of 90% probabil-
ity in assigning a sample to a lymphoma type based on thesesome patients may survive more than 10 years.
Faced with this clinical heterogeneity, many attempts have binary predictors.
To insure the reproducibility of our method, we divided thebeen made to develop prognostic markers of survival. Several
morphological subtypes of MCL have been recognized, and a cyclin D1-positive MCL cases into two equal groups: a “training
set” that was used to develop the MCL diagnostic test, and ablastic variant of MCL has been associated with short survival
in several studies (Argatoff et al., 1997; Bosch et al., 1998; “validation set” that was used to evaluate the test. We optimized
the number of genes in each binary lymphoma type predictorLardelli et al., 1990). High tumor cell proliferation has also been
associated with shorter survival (Argatoff et al., 1997; Bosch et so as to minimize the number of classification errors when the
predictor was applied to the training set cases in a crossvalida-al., 1998; Raty et al., 2002; Velders et al., 1996), as has INK4a/
ARF locus deletion (Dreyling et al., 1997; Pinyol et al., 1998) tion, leave-one-out fashion. We deliberately excluded cyclin D1
as a lymphoma type distinction gene because we wished toand p53 mutation or protein overexpression (Greiner et al., 1996;
Hernandez et al., 1996; Louie et al., 1995). However, the prog- apply our model to potential MCL cases that were cyclin D1-
negative. Using the optimized lymphoma type predictors, 100%nostic groups defined by each of these markers were still clini-
cally heterogeneous, demonstrating that each marker alone of the training set cases were correctly classified (Figure 1B).
When applied to the validation set, the model correctly classifieddoes not fully account for the clinical behavior of these tumors.
In the present study, our first goal was to establish a molecu- 98% of the cyclin D1-positive MCL cases as MCL, thus establish-
ing this method as a reliable MCL diagnostic test (Figure 1B).lar diagnosis of MCL based on gene expression that could
reliably distinguish this disease from other lymphoma types. We applied this MCL diagnostic test to 9 lymphoma cases
that were morphologically consistent with MCL but were nega-With such a diagnostic test in hand, we investigated which
genes had expression patterns that correlated with length of tive for cyclin D1 expression by quantitative RT-PCR analysis.
Seven were classified as MCL, one was classified as GCBsurvival. We show that genes involved in proliferation have an
DLBCL, and one was not assigned to any lymphoma groupoverriding influence on the clinical course and can be used
based on the probability cutoff used. As shown in Figure 1C,to construct a powerful predictor of survival. Additionally, we
the 7 cyclin D1-negative MCL tumors were comparable to cyclindemonstrate that the proliferation signature integrates several
D1-positive MCL tumors with respect to expression of 42 MCLoncogenic mechanisms in MCL that govern the cell cycle, lead-
signature genes. Interestingly, 2 of these cyclin D1-negativeing us to propose a quantitative model for MCL pathogenesis.
tumors expressed higher levels of cyclin D3, and 1 expressed
higher levels of cyclin D2 than were detected in cyclin D1-Results
positive MCLs. At present, the molecular mechanisms underly-
ing the expression of other D-type cyclins in these cases areMolecular diagnosis of MCL
To establish a molecular diagnosis of MCL based on gene ex- unclear, but this finding suggests that these tumors may have
found alternative ways to increase cell cycle progression in thepression, we began by identifying lymphoma cases that were
morphologically consistent with this diagnosis upon pathologi- absence of cyclin D1. Overall survival of patients with cyclin
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D1-positive MCL was not statistically different from that of pa- To visualize the predictive power of our survival model, we
ranked the patients according to the expression of the prolifera-tients with cyclin D1-negative MCL (Figure 1D).
tion signature genes in their tumors, and divided them into 4
equal quartiles. Figure 2B shows Kaplan-Meier plots of overallA gene expression-based predictor of survival
We next used gene expression to develop a predictor of length survival of patients in each of these quartiles, within the training
set, the validation set, and the total set of cases. These plotsof survival following diagnosis of MCL. The median survival of
the patients with cyclin D1-positive MCL was 2.8 years, but the indicate that the proliferation signature can identify patient sub-
sets with strikingly different survival times. The median survivallengths of survival were quite heterogeneous (Figure 1D). Many
patients died within the first 2 years following diagnosis, yet times of patients in the four quartiles were: 6.71 years (quartile
1), 3.28 years (quartile 2), 2.31 years (quartile 3), and 0.83 years15% (14/92) of the patients survived more than 5 years and 3
patients survived more than 10 years. It is important to empha- (quartile 4). It is important to emphasize that the quartile method
that we used to group MCL patients is merely a way of illustratingsize that the diagnosis of MCL in these patients was based on
morphology, cyclin D1 expression, and expression of genes the quantitative relationship between proliferation and survival.
The proliferation signature average is a continuous variable thatthat distinguish MCL from other non-Hodgkin’s lymphomas.
Thus, the differences in survival among these patients are un- assigns, for each patient, a discrete probability of survival at
every time point following diagnosis. The proliferation signaturelikely to be due to the inadvertent inclusion of other lymphoma
types in our cohort. average varied over a 13.5-fold range and a 2-fold increase in
the proliferation signature average corresponded to a 3.6-foldWe used a supervised approach to discover “survival predic-
tion” genes with expression patterns that were associated with increased relative risk of dying.
Several histological subtypes of MCL can be discerned, andlength of survival among MCL patients in the training sets. The
expression levels of 48 genes correlated with survival with high these have been shown to differ with respect to proliferation
rate and survival (Argatoff et al., 1997; Bosch et al., 1998).statistical significance (p  0.001), and all of these were more
highly expressed in tumors from patients with short survival. We subdivided our MCL cases by morphology into classical
(68.4%), blastic (9.8%), pleomorphic (6.5%), and small cellAs in our previous analysis of survival of patients with DLBCL
(Rosenwald et al., 2002), we functionally classified the survival (9.8%) subtypes. As expected, the cases with blastic morphol-
ogy had the highest expression of the proliferation signatureprediction genes based on their membership in gene expression
“signatures.” A gene expression signature is a group of genes (Figure 3A) and the shortest survival (Figure 3B). However, the
morphological categorization of MCL was a much weaker pre-that are coordinately expressed in association with a particular
biological process (Shaffer et al., 2001). Notably, 58% of the dictor of survival (p  5.7  103) than was the proliferation
signature.survival prediction genes (28/48) belonged to the proliferation
gene expression signature. This signature is composed of genes
that are expressed at higher levels in dividing cells than in quies- The proliferation signature integrates oncogenic
events associated with survivalcent cells, including genes required for DNA replication, cell
cycle progression, and the metabolic demands of proliferation Having related the proliferation signature to overall survival in
MCL, we searched for molecular mechanisms that might explain(Shaffer et al., 2001). We further focused our attention on those
survival prediction genes that were most variably expressed the variable proliferation of MCLs. We noted that the mRNA
expression of the cyclin D1 coding region, as measured by aamong the MCLs (i.e., in the top third of gene expression vari-
ance) in order to facilitate the subsequent analysis of these quantitative RT-PCR assay, was higher in more proliferative
MCLs (p  1.4  104; Figure 4A). Further, the abundance ofgenes by other methodologies; 34 genes satisfied this selection
criterion, of which 20 belonged to the proliferation signature. cyclin D1 coding region mRNA was a univariate predictor of
survival (p  4.69  104), but was not as strong a prognosticWe averaged the expression levels of these 20 genes to create
a proliferation signature average for each MCL case. Tumor cell marker as the proliferation signature (Figure 4E). The expression
of cyclin D1 coding region mRNA was correlated with prolifera-proliferation rate can also be estimated by the number of Ki67-
positive cells or by the mitotic index, and these data were avail- tion (p 1.4 104), and therefore did not add to the prognostic
strength of the proliferation signature in a 2-component model.able on 14 patients. As expected, the proliferation signature
average was correlated with the number of Ki67-positive cells These results suggests a direct relationship between cyclin D1
expression levels and proliferation rate in MCL, and demonstrate(r  0.69) and the mitotic index (r  0.62).
Within the training set, the proliferation signature average that the length of survival of MCL patients depends upon quanti-
tative differences in progression from G1 to S phase of the cellwas inversely correlated with survival with high statistical sig-
nificance (1.92  105). Importantly, the proliferation signature cycle.
MCLs can express various cyclin D1 mRNA isoforms thataverage also predicted survival of patients in the validation set
with high significance (7.44  105), thus demonstrating the all include the cyclin D1 coding region but that differ in the
length of their 3 untranslated regions (UTRs) (Figure 4G). Thereproducibility of this gene expression-based predictor. When
all cases were considered together, this predictor correlated with 4.5 kb mRNA isoform has an extended UTR that includes an
AT-rich segment with the potential to decrease mRNA stabilitysurvival with a significance of p 5.07 109. None of the other
survival prediction genes from the original set of 48 improved (Lebwohl et al., 1994; Lin et al., 2000; Rimokh et al., 1994). Some
MCLs have alterations in the cyclin D1 genomic sequences thatthe prognostic ability of the proliferation signature average in
multivariate models. Of note, we could also construct a model encode the 3 UTR region, and these cases do not express the
4.5 kb mRNA isoform, but instead express a 1.7 kb mRNAfrom only 4 proliferation signature genes (CDC2, ASPM, tubulin
, CENP-F) that predicted length of survival with high statistical isoform or other short mRNAs that lack the potential mRNA
destabilizing element in the 3 UTR (Bosch et al., 1994; de Boersignificance on the total set of cases (p  2.67  108).
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Figure 2. A gene expression-based predictor of
survival
A: Relative expression of 20 proliferation signa-
ture genes that were used to compute the prolif-
eration signature average. Cyclin D1-positive
MCL cases are ordered according to their ex-
pression of the proliferation signature average.
The color scale depicts gene expression over a
4-fold range.
B: Kaplan-Meier plots of overall survival ac-
cording to a survival predictor based on the pro-
liferation signature average. Separate plots are
shown for patients in the training set and the
validation set and for all patients combined. For
visualization, patients were ranked according to
their proliferation signature average and divided
into 4 equal quartiles.
et al., 1995; Rimokh et al., 1994; Seto et al., 1992; Withers et With some MCL samples, we obtained little if any signal
from the cyclin D1 3 UTR features on the microarray, yet theseal., 1991). On the Lymphochip DNA microarray, the cyclin D1
features correspond to the extended 3 UTR, and therefore can same samples had abundant expression of the cyclin D1 coding
region as assessed by the quantitative RT-PCR assay (Figureonly detect expression of the 4.5 kb mRNA. In contrast, the
quantitative RT-PCR assay for the cyclin D1 coding region can 4A). This pattern suggests that these MCL tumors preferentially
express the short cyclin D1 mRNA isoforms lacking the ex-detect shorter isoforms lacking the extended 3 UTR as well as
the 4.5 kb isoform. tended 3 UTR. Notably, the MCLs with this expression pattern
Figure 1. Molecular diagnosis of mantle cell lymphoma
A: Hierarchical clustering of expression measurements from 42 MCL signature genes that are more highly expressed in 92 MCL samples than in 20 SLL, 83
ABC LBCL, and 134 GCB DLBCL samples (see text for details). Each column represents a single lymphoma specimen, and each row represents expression
of a single gene. Red squares indicate increased expression and green squares indicate decreased expression relative to the median expression level
according to the color scale shown. The right panel shows the median gene expression for the 42 MCL signature genes in each of the lymphoma subgroups.
B: Performance of the gene expression-based diagnostic test for MCL in each of the three models (MCL versus ABC DLBCL, MCL versus GCB DLBCL, and
MCL versus SLL) in the “training set” and in the “validation set” of cases.
C: Expression of MCL signature genes in seven cyclin D1-positive and seven cyclin D1-negative lymphoma cases. Cyclin D1-negative cases had MCL
morphology and immunophenotype and were classified as MCL based on their gene expression profile. Shown below is the relative gene expression of
cyclin D1 (as measured by quantitative RT-PCR) and cyclins D2 and D3 (as measured by DNA microarray analysis).
D: Kaplan-Meier estimates of overall survival of patients with cyclin D1-positive and cyclin D1-negative MCL.
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Figure 3. Proliferation and survival rates in different histological subtypes of MCL
A: Proliferation signature averages in the classic, blastic, pleomorphic, and small cell subtypes of MCL. The dots represent the mean value within each
class, and the bars represent the standard error of that mean estimate.
B: Kaplan-Meier plots of overall survival of patients in different histological MCL subtypes.
were generally among those with high proliferation (Figure 4A). tical model of survival, such that the combined model had a
greater significance (p  3.59  106) than models of survivalBased on levels of cyclin D1 3 UTR expression, we defined a
“3 UTR low” group of 17 MCL cases and a “3 UTR high” group based on either of these components alone (Figure 5C).
Deletional events at the p53 and ATM loci had distinct butof 75 MCL cases (Figure 4B). The 3 UTR low group had a 1.58-
fold higher level of cyclin D1 coding region mRNA than did the overlapping distributions with respect to each other and with
respect to INK4a/ARF locus deletions (Figure 5A). p53 deletions3UTR high group (p 5.4 105), thus providing one potential
molecular mechanism for the variable expression of cyclin D1 were found in 9 MCL cases (11%), and concurrent deletions
of INK4a/ARF locus and ATM were found in 3 and 6 cases,coding region mRNAs (Figure 4C). Further, the 3UTR low group
had a 1.83-fold higher expression of the proliferation signature respectively. ATM deletions were more frequent among the
MCLs, occurring in 30 cases (35%), and were concurrent with(p  1.3  107; Figure 4D) and a shorter survival than the 3
UTR high group (p  7.97  105; Figure 4F). INK4a/ARF locus and p53 deletions in 8 and 6 cases, respec-
tively. These findings suggest that loss of these tumor suppres-We next investigated whether deletions of tumor suppressor
genes were associated with proliferation rate and survival in sor genes provided nonredundant selective advantages to the
MCLs during the natural histories of these lymphomas. p53MCL. We used a quantitative PCR assay to detect genomic
loss of one or both alleles of the INK4a/ARF locus, which en- deletions were not strongly associated with proliferation (Figure
5A) or survival (p 0.25; data not shown), although the numbercodes two tumor suppressors, p16INK4a and p14ARF. INK4a/ARF
locus deletions were detected in 21% (18/85) of the cases and of p53 deletional events in our series was small, and some
MCL cases may have mutations of p53 without deletion. ATMwere preferentially observed among the more proliferative MCLs
(Figure 5A). The INK4a/ARF locus can also be transcriptionally deletions were present in tumors with both low and high prolifer-
ation rates (Figure 5A), and had no apparent relationship tosilenced by the polycomb family protein BMI-1 (Jacobs et al.,
1999), and BMI-1 is amplified and/or overexpressed in some survival (p  0.66; data not shown).
MCLs (Bea et al., 2001). Notably, BMI-1 was overexpressed in
some highly proliferative MCLs that lacked INK4a/ARF locus Discussion
deletion (Figure 5A).
We next tested whether the proliferation rate of MCL tumors We have taken a quantitative approach to understand the patho-
genesis of MCL and to account for the variable survival of thesecould be modeled using a combination of the INK4a/ARF locus
deletional status and the expression of cyclin D1 coding region patients. By precisely measuring the expression of genes asso-
ciated with proliferation, we found that the degree of tumor cellmRNA. Both of these parameters added independently to a
model of survival: cyclin D1 coding region expression added to proliferation provides a powerful predictor of survival for this
lymphoma. Further, our approach provides a quantitative ratherthe significance of a model based on INK4a/ARF locus deletion
alone (p  2.6  103), and INK4a/ARF locus deletion added than qualitative framework for the molecular pathogenesis of
this disease, in which higher cyclin D1 mRNA levels are reflectedto the significance of a model based on cyclin D1 coding region
expression alone (p  3.6  105). This finding suggests that in higher tumor cell proliferation and shorter survival.
The defining oncogenic event in most MCLs is translocationincreased cyclin D1 expression and INK4a/ARF locus deletion
cooperate mechanistically to increase the proliferation rate (see and overexpression of cyclin D1, and this shared pathogenetic
feature was central to the success of our quantitative approach.Discussion). INK4a/ARF locus deletions were also associated
with shorter survival (p 4.88 104; Figure 5B). Again, INK4a/ Using an RT-PCR assay, we defined a cohort of patients whose
tumors expressed cyclin D1 and found that they also expressedARF locus deletional status and cyclin D1 coding region expres-
sion added independent predictive power to a combined statis- a set of MCL signature genes that distinguished this lymphoma
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Figure 4. Relationship between cyclin D1 expression, proliferation, and survival in MCL
A: Relative cyclin D1 mRNA expression of the coding region (measured by quantitative RT-PCR, upper panel) and of the 3 UTR (measured by DNA
microarray analysis). The 92 cyclin D1-positive MCL cases are ordered according to their proliferation signature average (lower panel). The cyclin D1
expression is depicted over a 9-fold range, whereas the proliferation signature expression is depicted over a 4-fold range.
B: Histogram of cyclin D1 3 UTR levels. Shown is a cutpoint that divides the MCL cases into a “3 UTR low” group (17 cases) and a “3 UTR high” group (75
cases).
C: Level of cyclin D1 coding region mRNA in the “3 UTR low” and “3 UTR high” groups of MCL. The dots represent the mean value within each class, and
the bars represent the standard error of that mean estimate.
D: Proliferation signature averages of MCL cases in the “3 UTR low” and “3 UTR high” groups of MCL. The dots represent the mean value within each
class, and the bars represent the standard error of that mean estimate.
E: Kaplan-Meier estimates of overall survival according to the level of cyclin D1 coding region mRNA expression.
F: Kaplan-Meier plot of overall survival according to cyclin D1 3UTR expression.
G: The cyclin D1 locus: alternative 3 polyadenylation sites can result in the expression of a short (1.7 kb) and a long (4.5 kb) cyclin D1 mRNA.
CANCER CELL : FEBRUARY 2003 191
R E P O R T
Figure 5. Deletions of INK4a/ARF, ATM, and p53
loci in MCL
A: Genomic loss of one or both alleles of the
INK4a/ARF, ATM, and p53 loci as measured by
quantitative PCR. MCL cases are ordered by
their proliferation signature averages, and dele-
tions are indicated by yellow squares. Black
squares indicate wild-type configuration of the
genomic loci, and gray squares indicate missing
data. BMI-1 expression is depicted over a 9-fold
range.
B: Influence of INK4a/ARF locus deletion on over-
all survival.
type from others. By basing our molecular diagnosis on the proliferation in MCL relied on semiquantitative methods such
as the mitotic index or immunohistochemical staining for Ki67expression of cyclin D1 and the MCL signature genes, we could
be confident that we were studying patients with highly related to define patient groups that differed in survival by only 2.1–2.7
years (Argatoff et al., 1997; Bosch et al., 1998; Raty et al., 2002;cancers, which is critical when searching for the molecular de-
terminants of survival. Velders et al., 1996).
Since our quantitative method accounts more fully for theThe MCL gene expression signature further allowed us to
identify a new subtype of MCL that is cyclin D1-negative. The varying survival of MCL patients, it could prove useful in the
clinical management of these patients. Since the proliferationexistence of cyclin D1-negative MCL has been controversial,
since other methods of detecting cyclin D1 translocations or signature can be faithfully represented by as few as 4 genes,
a limited set of quantitative RT-PCR assays could be used toexpression vary in sensitivity, and since other lymphoid malig-
nancies can express cyclin D1. We identified a group of lympho- assess tumor proliferation rate. In particular, we suggest that
clinical trials in MCL should incorporate a quantitative measuremas that were not only morphologically indistinguishable from
cyclin D1-positive MCLs, but also shared expression of MCL of tumor proliferation rate. This would enable a direct compari-
son of the patients enrolled in different clinical trials and wouldsignature genes. These patients with cyclin D1-negative MCL
did not differ significantly in survival from patients with cyclin provide a rational basis by which to compare trial results.
Various intensified treatments are being evaluated in MCL,D1-positive MCL. Interestingly, some of the cyclin D1-negative
MCLs expressed either cyclin D2 or D3, suggesting that these including autologous and allogeneic bone marrow transplanta-
tion, modified chemotherapeutic regimens, and radioimmuno-cyclins can functionally substitute for cyclin D1 in MCL. At pres-
ent, we do not know whether the expression of the other D-type therapy (Barista et al., 2001; Gopal et al., 2002; Leonard et al.,
2001). Our results suggest that it may be beneficial to stratifycyclins in these cases is due to genomic rearrangements of
these genes or to increased transcription. Given the importance patients for entry into clinical trials of these regimens according
to the expression of proliferation signature genes in their tumors.of the G1/S phase transition in MCL, it is highly likely that all
of the cyclin D1-negative MCL tumors have acquired some Clinical trials of intensified regimens might be designed to enroll
only those patients whose tumor proliferation rate predicts anmechanism to accelerate entry into S phase.
Among patients with cyclin D1-positive MCL, the prolifera- exceedingly short survival. Intensified regimens may not be ap-
propriate for patients whose tumor proliferation rate predicts ation signature was the sole gene expression feature that was
significantly associated with survival. Using the proliferation sig- longer survival, since these regimens may not prolong the sur-
vival of these patients and may unnecessarily expose themnature average as a metric, we identified one quartile of MCL
patients who had a median survival of 6.7 years, which is excep- to treatment-related toxicities. Rather, these patients could be
managed conservatively, with relatively nontoxic therapies giventionally long for this incurable malignancy. At the other end
of the spectrum, we identified a quartile of patients who had only as clinically indicated.
In addition to its value in prognosis, the proliferation signa-particularly aggressive tumors and a median survival of only 0.8
years. This 5.9-year difference in survival highlights the potential ture proved very useful in establishing a quantitative model
of MCL pathogenesis. In particular, the proliferation signaturevalue of the proliferation gene expression signature as a prog-
nostic test in MCL. By contrast, previous analyses of tumor cell quantitatively integrated the effects of cyclin D1 expression and
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deletion of the INK4a/ARF locus. However, our statistical model D1 kinase complexes. Our data demonstrate that small changes
in the expression of D-type cyclins can have significant effectsbased on cyclin D1 expression and INK4a/ARF deletions ac-
counted for only 32% of the variation in the proliferation signa- on tumor cell proliferation and the clinical course of cancer
patients.ture average (data not shown), and therefore the proliferation
signature may also reflect additional oncogenic events that are High expression of the proliferation signature in MCL was
also associated with deletion of the INK4a/ARF locus. This locusas yet unknown.
Higher expression of cyclin D1 mRNA was correlated with encodes two structurally unrelated tumor suppressors, p16INK4a
and p14ARF (Sherr and McCormick, 2002), and deletions of thisincreased proliferation and decreased survival time. The impor-
tance of this oncogenic mechanism in MCL has been overlooked genomic region in MCL typically inactivate both the p16INK4a and
p14ARF genes and are frequently homozygous (Dreyling et al.,since previous studies have used only semiquantitative methods
to assess cyclin D1 expression and tumor proliferation. We 1997; Pinyol et al., 1997, 1998, 2000). Further, the p16INK4a gene
does not sustain point mutations in MCLs as it does in melanomanoted that many of the highly proliferative MCL tumors ex-
pressed mRNA species that contained the cyclin D1 coding and other cancers (Pinyol et al., 1997, 2000). Finally, we and
others (Bea et al., 2001) observed overexpression of the BMI-1region but not the extended 3 UTR region, and this was associ-
ated with higher levels of cyclin D1 coding region expression. gene in MCLs that lacked deletion of the INK4a/ARF locus,
which is notable since BMI-1 represses transcription of bothMCLs and other cancers have been shown to variably express
cyclin D1 mRNA isoforms that differ in the length of their 3 p16INK4a and p14ARF (Sherr and McCormick, 2002). These consid-
erations suggest that the INK4a/ARF deletions in MCL may beUTRs. The extended 3 UTR of the 4.5 kb cyclin D1 isoform
contains AT-rich sequences that can modulate the stability of selected to circumvent the actions of both p16INK4a and p14ARF.
p16INK4a regulates the G1/S phase transition by forming bi-the mRNA, and short cyclin D1 mRNA isoforms lacking this
region are more stable (Lebwohl et al., 1994; Lin et al., 2000; nary complexes with cdk4 and cdk6, thereby preventing these
subunits from associating with molecular chaperones that pro-Rimokh et al., 1994). In some MCLs, the genomic region corre-
sponding to the extended 3 UTR is deleted or rearranged, and mote their association with D-type cyclins (reviewed in Sherr
and McCormick, 2002). p16INK4a deletion and increased cyclinthese cases lack expression of the 4.5 kb mRNA isoform (de
Boer et al., 1995; Rimokh et al., 1994; Seto et al., 1992; Withers D1 expression may therefore promote the G1/S phase transition
by the same mechanism. Nonetheless, our statistical modelset al., 1991). However, in some cells, the 4.5 and 1.7 kb isoforms
coexist, and their relative abundance may be regulated by alter- demonstrated that cyclin D1 expression and INK4a/ARF dele-
tions cooperated to quantitatively increase proliferation andnative polyadenylation and cleavage (Xiong et al., 1991). Re-
gardless of the mechanism, our data demonstrate that selective shorten survival. One model to account for this oncogenic syner-
gism would propose that the presence of wild-type levels ofexpression of short cyclin D1 mRNA isoforms is a pathogenetic
mechanism that is associated with increased cyclin D1 expres- p16INK4a blunts the effect of increased cyclin D1 expression by
preventing cyclin D1 from forming active kinase complexes.sion, more rapid proliferation, and shorter survival.
The relationship between increased cyclin D1 expression Although many cancer types have disruption in only one compo-
nent of the Rb pathway (Sherr and McCormick, 2002), our resultsand increased proliferation suggests a quantitative model for
the G1/S phase transition. In this model, an increase in the suggest that some cancers may accumulate multiple oncogenic
lesions that cooperate to quantitatively interfere with this path-intracellular concentration of cyclin D1 promotes its assembly
into active kinase complexes with cdk4 and cdk6 (cyclin D1/ way and promote proliferation.
Studies of mouse strains with selective disruption of thecdk4[6]), which would enhance the frequency at which the cell
enters S phase by two mechanisms (reviewed in Sherr and p14ARF gene demonstrate that p14ARF also regulates proliferation.
p14ARF-deficient mouse embryo fibroblasts and pre-B cells di-McCormick, 2002). Cyclin D1/cdk4(6) kinases phosphorylate
the retinoblastoma (Rb) gene product and thereby promote the vide more rapidly than their wild-type counterparts and fail to
senesce during repeated passaging in vitro (Kamijo et al., 1998;release of E2F transcription factors that are required in S phase.
Further, cyclin D1/cdk4(6) complexes interact with the cyclin- Randle et al., 2001). Further, in transgenic mice overexpressing
c-myc, p14ARF-deficiency accelerates lymphoma formation anddependent kinase inhibitors p21 and p27kip1 and titrate these
factors away from cyclin E/cdk2 kinase complexes. Whereas the proliferation rate of the malignant B cells ex vivo (Eischen
et al., 1999; Schmitt et al., 2002). Although the mechanismsp21 and p27kip1 are potent inhibitors of cyclinE/cdk2, they
fail to inhibit cyclin D1/cdk4(6). Increased cyclin E/cdk2 kinase underlying the enhanced proliferation of p14ARF-deficient cells
are not completely understood, these observations suggest thatactivity promotes S phase entry by phosphorylating Rb and
can sustain cell cycle progression by phosphorylating p27kip1, loss of p14ARF may contribute to the enhanced proliferation of
INK4a/ARF-deleted MCL tumors.leading to its degradation in the proteosome. In keeping with
this model, most p27kip1 in MCL cells is biochemically associ- An important function of p14ARF is to augment p53 function
by antagonizing MDM2 (Sherr and McCormick, 2002), and lossated with cyclin D1 (Quintanilla-Martinez et al., 2003).
Our findings highlight the quantitative sensitivity of the G1/S of this p14ARF function may contribute to the enhanced prolifera-
tion and shorter survival of MCL patients with INK4a/ARF dele-phase transition to changes in D-type cyclin concentration. This
cell cycle transition appears to behave like a rheostat regulated tions. p14ARF is induced by a variety of oncogenes that promote
inappropriate proliferation, leading to a p53-dependent cell cy-by cyclin D1 kinase complex levels rather than an on/off switch
that is activated when a threshold level of cyclin D1 is achieved cle arrest or apoptosis (Kamijo et al., 1997, 1998). In MCL tumors
with wild-type INK4a/ARF loci, it is conceivable that some onco-(see Sherr and Roberts, 1995, 1999 for a complete discussion).
In this model, the fraction of cells in the tumor clone that are genic stimuli may activate p14ARF and constrain proliferation. In
this scenario, MCL tumor cells that sustain p14ARF deletionsin G1 phase, and consequently the tumor proliferation rate,
would be influenced quantitatively by the abundance of cyclin would have a selective advantage. Our observation that INK4a/
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ples, as described previously (Rosenwald et al., 2002). The complete geneARF locus deletions and cyclin D1 expression synergize to pre-
expression data set is available at http://llmpp.nih.gov/MCL.dict the proliferation signature may therefore reflect a coopera-
tion between the p53 pathway and the RB pathway in controlling
Real-time quantitative PCR
cell cycle progression. However, we found that some MCL tu- To measure cyclin D1 mRNA expression by real-time quantitative RT-PCR,
mors had deletions of both the INK4a/ARF and p53 loci, sug- an aliquot of the mRNA used for the microarray experiments was diluted to
approximately 0.5 ng/l. 5 l of the diluted mRNA were used for eachgesting that p53 deletion may provide additional selective ad-
RT-PCR reaction using TaqManTM reagents and analyzed on an Appliedvantages, such as evasion of apoptosis.
Biosystems Thermal Cycler. All samples were run in triplicate, and a probeThough many of the oncogenic events in MCL are designed
for the 2-microglobulin gene was chosen as a reference. Primers andto promote S phase entry, deletions of the ATM tumor suppres-
Taqman probes for both 2-microglobulin and the coding region of cyclin
sor gene appear to play a different role. Roughly one-third of D1 have been described previously (Bijwaard et al., 2001).
the MCL tumors in our study had ATM deletions, irrespective To detect genomic loss of the INK4a/ARF, ATM, and p53 tumor suppres-
of tumor proliferation rate, INK4a/ARF locus deletional status, sor loci in the tumor specimens, we performed quantitative real-time PCR
assays using genomic DNA. The REL locus on chromosome 2p was chosenand cyclin D1 expression and survival. This finding suggests
as a reference gene based on comparative genomic hybridization studiesthat the tumor suppressor role of ATM in MCL is unrelated
that showed only infrequent genomic alterations in this chromosomal regionmechanistically to G1/S phase checkpoint. ATM is required for
in MCL (Bea et al., 1999; Bentz et al., 2000). Eight control DNA samples
activation of p53 in response to DNA damage and abnormal were prepared from peripheral blood mononuclear cells of 5 different healthy
telomeres, and during normal immunoglobulin V-D-J recombi- volunteers. The ratios of INK4a/ARF locus, ATM, and p53 amplification rela-
nation (Karlseder et al., 1999; Kastan et al., 1992; Perkins et tive to REL amplification were calculated for each control sample. We used
these control ratios to establish cutoff ratios that we used to assess tumoral., 2002). However, ATM deletions coincided with p53 deletions
DNAs for genomic deletions. For each gene, this cutoff ratio was set as thein several MCL cases, suggesting that loss of these genes may
mean ratio minus 3 standard deviation units; the cutoffs for the INK4a/serve distinct functions in the pathogenesis of some MCLs.
ARF locus/REL, ATM/REL, and p53/REL ratios were 0.67, 0.72, and 0.7,Finally, our data provide quantitative insights into the poten-
respectively. A tumor DNA sample that yielded an amplification ratio below
tial of cell cycle inhibitors in the therapy of MCL. Although cell the cutoff ratio for a particular tumor suppressor gene was considered to
cycle inhibitors would not necessarily be curative in MCL, it is have a genomic deletion of that gene.
We used previously described primer and TaqMan probe sets for thepossible that they could alter its natural history, yielding a
INK4a/ARF locus that were situated in exonic regions that are shared bychronic lymphoproliferative disease that could be managed
p16INK4a and p14ARF (Labuhn et al., 2001). The primers used for the REL locusconservatively. Could, for example, a cell cycle inhibitor shift a
have also been described (Goff et al., 2000). Primers for ATM amplificationpatient’s lymphoma from the last to the first quartile of the
were 5-CCCAGACCGCCAATCTCAT (sense) and 5-ATGGAGTGAGGAGA
proliferation signature average, thereby prolonging the patient’s GGGAGGA (antisense), and for p53, 5-GGGACCTCTTATCAAGTGGAAA
survival by more than 5 years? An inhibitor targeting the basic (sense) and 5-CCCAATTGCAGGTAAAACAGTCA (antisense). Gene-specific
cell cycle machinery would likely require careful dose titration fluorescent probes for ATM and p53 were 5-FAM-CACCCCTCCAGAGTGG
CCCTTGA-TAMRA (sense) and 5-FAM-TTTCCAGTCTAACACTCAAAATGCin order to limit toxicity during chronic administration. Alterna-
CGTTTTCTT-TAMRA (sense), respectively.tively, it is possible that inhibitors that target the G1/S check-
point by disrupting cyclin D1/cdk4(6) complexes could be ad-
Statistical methods
ministered chronically, and might turn MCL into a clinically Bayesian formulation of a discrimator between two
manageable disease. lymphoma subtypes
The method we used to formulate our predictor of MCL was based on a
Experimental procedures variation of the compound covariate predictor (Radmacher et al., 2002).
Although our complete method involved the distinction between MCL and
Patients several different classes of samples, we begin by describing a general
Tumor biopsies from 101 untreated patients with no history of a previous method for estimating the probability that a given sample is in one of two
lymphoma were included in the present study, according to a protocol groups, based on data from a fixed training set.
approved by the National Cancer Institute institutional review board. Tumor We begin with a gene selection step. For each gene in our training set,
histology was reviewed by a panel of 8 hematopathologists, and 92 biopsy we calculated the t statistic for the difference in the expression of that gene
specimens were classified as mantle cell lymphoma, based on established between the two groups. After our data set was so reduced to include
morphologic and immunophenotypic criteria (Jaffe et al., 2001). All of these only unique genes, we choose the k genes with most statically significant t
92 cases showed overexpression of cyclin D1 mRNA by a quantitative RT- statistics to use in our predictor. In order to avoid redundancy, when multiple
PCR assay and, in most cases, immunohistochemistry demonstrated over- spots for a given gene were found on the array, we only considered the
expression of cyclin D1 also on the protein level. In the remaining nine spot that gave the most statistically significant t statistic. This resulted in a
lymphoma specimens, the morphology and immunophenotype of the tumor list of k unique genes that were variably expressed between the two groups.
cells were consistent with the diagnosis of MCL, but there was no evidence The method we used to choose k will be discussed later.
of the t(11;14) translocation or cyclin D1 protein expression. All nine of these Given a training sample, the standard 2-group compound covariate
cases were negative for cyclin D1 mRNA expression by quantitative RT- predictor associates with each sample a compound covariate score (CCS)
PCR. Only data obtained from the 92 patients with cyclin D1-positive MCL given by




tjXj,these 92 patients, 72 were male and 19 female (no information was available
on one patient), the median age at diagnosis was 61.5 years (range 38 to 92.5
years) and median survival was 2.8 years. 84 patients received multiagent where tj is the t statistic for the two-group comparison of the log ratios for
chemotherapy as needed symptomatically, 6 received no treatment, and no gene j in the training set, and Xj is the log ratio for gene j of the sample.
information on treatment was available in 2 patients. This sum is taken over the k most significant t statistics. This produces a
score for which high values indicate likely membership in group 1 and low
Microarray procedures values indicate likely membership in group 2.
Lymphochip DNA microarrays (Alizadeh et al., 1999) containing 12,196 cDNA Radmacher et al. suggest classifying a new sample based on whether the
CCS of this new sample was closer to the median of the CCSs in each group.elements were used to quantitate mRNA expression in the lymphoma sam-
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This works well, but does not allow one to make a statement concerning the Other statistical methods
Survival curves and median survival times were estimated using the Kaplan-amount of confidence one has in such an assignment. According to Bayes’
rule (Bayes, 1763), we can estimate the probability of a new sample Y being Meier method. When estimating the association of parameters with survival,
Cox proportional hazards models were fit. For continuous variables, (prolifer-within one of the groups as
ation and cyclin D1 coding region expression), the likelihood ratio p value
P(Y in Group 1|CCS(Y)  was reported. For the categorical variables (tumor histology, high/low cyclin
D1 3 UTR, INK4a/ARF deletion, p53 deletion, and ATM deletion), the pP(CCS(Y)|Y in Group 1)
P(CCS(Y)|Y in Group 1) 	 P(CCS(Y)|Y in Group 2) . value from the log rank test was used. A Cox model was also fit to the
combination of the cyclin D1 coding region expression and an indicator of
Strictly speaking, there should be additional terms indicating the general INK4a/ARF deletion. For the purpose of displaying survival curves in Figure
prevalence of group 1 and group 2 in the population at large, but since we 5C, the samples were ranked according to this model and divided into
make no claims as to the representative nature of our patient sample, we quartiles. A likelihood ratio p value was reported from the combined model.
eliminated these terms, inherently assuming that Group 1 and Group 2 were A Spearman rank correlation test was used to indicate the association
equally prevalent. between proliferation and expression of the cyclin D1 coding region. When
Since CCS(X) is the linear combination of multiple measurements, it is not determining differences between the high/low cyclin D1 3 UTR in prolifera-
unreasonable to assume that the distribution of CCS(X) within each subgroup tion and cyclin D1 coding region expression, the p value from a 2-sided t
will be approximately normal. So if we let M1 and M2 be the sample means test was reported. t tests were also used to determine the extent to which
of CCS(X) within group 1 and group 2 of the training set, and s12 and s22 genes were differentially expressed between MCL and each other lymphoma
the respected sample variances, we can make the following estimate: subtypes. An ANOVA model was used to determine the extent to which
INK4a/ARF locus deletion and cyclin D1 coding region expression added
P(Y in Group 1)  constructively in their association with proliferation.
In forming the predictor of survival, we used those genes that wereφ(CCS(Y); M1,s12)
φ(CCS(Y); M1,s12) 	 φ(CCS(Y); M2,s22) found in the proliferation signature, were associated with poor prognosis in
the training set (p 0.001 according to a Wald test), and had larger variance
where φ represents the normal density. across the samples of the training set than 2/3 of the genes. When multiple
Lymphochip microarray features representing the same gene were found to







ated with survival on the training set was used. No survival information from
the validation set was used to generate the gene list. The expression data
For ease in notation we write
for each of these genes were mean centered across all samples, and the
proliferation signature average for a given sample was computed as theP1(Y)  P(Y in Group 1).
average of these mean centered observations. Missing values for genes
were excluded in taking this average.Formulation of a gene expression-based MCL diagnostic test
We began by equally dividing the gene expression data from MCL and other
Acknowledgmentslymphoma samples into a training set and a validation set. The training set
consisted of 46 MCL samples, 42 ABC samples, 67 GCB samples, and 11
We are very grateful to Chuck Sherr for helpful discussions and suggestions.SLL samples. The validation set was similarly composed, but had one fewer
ABC sample. Since our goal was to determine which genes other than cyclin
D1 were related to MCL, we excluded all cyclin D1 clones from this analysis.
In generating an MCL versus non-MCL predictor, a simple two class
Received: December 20, 2002predictor would be insufficient, since there was a great deal of structure
Revised: January 22, 2003within the non-MCL subset. Instead, we generated 3 separate 2-group pre-
dictors: MCL versus ABC, MCL versus GCB, and MCL versus SLL.
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